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Abstract  
Background: Multiple sclerosis (MS) is an autoimmune disorder that results in debilitating 
cognitive impairment in 40-65% of patients. There are no current treatments for this symptom of 
MS. This is a systematic review of literature on the impact amphetamines have on cognitive 
function of MS patients.  
Methods:  An exhaustive search of available medical literature was conducted using MEDLINE-
Ovid, MEDLINE-PubMed, Web of Science, and CINAHL. Keywords used included: 
amphetamines and multiple sclerosis. Relevant articles were assessed for quality using GRADE. 
Results:  Three studies have statistically significant improvements in some aspects of cognitive 
function in patients on amphetamines when compared to placebo. However, a high rate of 
adverse events were noted with L-isomer or D-isomer amphetamines alone.  
Conclusion:  Amphetamines positively impact cognitive function in MS patients. Mixed 
amphetamine salts extended release (MAS-XR) seemingly have the lowest rate of adverse effects 
with the greatest benefit per the Morrow & Rosehart study. Further research is needed to 
integrate this into a clinical setting.  
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BACKGROUND 
 Multiple sclerosis (MS) is a debilitating autoimmune disorder in which inflammation 
causes demyelination of the central nervous system. Cognitive impairment affects 40-65% of 
patients with MS and there is no current cure.1 While most treatments only target the physical 
deficits caused by the disease, cognitive impairment alone in MS patients negatively impacts 
work performance2 and may also influence relationships and decrease quality of life.3  
 Amphetamines are a stimulating class of drugs that increase the release of dopamine and 
inhibit the reuptake of dopamine in the brain. They are most commonly used to treat attention 
deficit hyperactivity disorder (ADHD), but they have been shown to increase working memory 
and attention in other mental illnesses as well.1 The concerns with this treatment are the potential 
for adverse events as well as abuse of medication. Amphetamines are among the top abused 
prescription medications in the US.4 There are also well-documented reports of adverse effects 
from amphetamines impacting development and causing central toxicity and psychological 
issues such as insomnia, negative affect, irritability, anxiety, and stimulant induced psychosis.4 
However, in a recent review of more than 100 studies, amphetamines and amphetamine 
containing medications are well-tolerated by most patients even when taken for several years.4  
 The literature reveals that several types of amphetamines have been trialed to treat 
cognitive deficits in MS. The first inquiries into this topic stemmed from the use of 
amphetamines found to improve memory and attention not only in ADHD but also in 
schizophrenia.1 Further research reveals that amphetamines improve reaction times, 
visual/spatial attention tasks, and the accuracy of working memory in patients with traumatic 
brain injury.5 The nature of impairment to the brain in MS is similar to an injury, but by an 
autoimmune process rather than direct trauma. Due to the lack of treatment for MS patients with 
cognitive deficits and this connection in literature linking amphetamines and cognitive 
improvement, this area of research has begun to develop. This review aims to assess the evidence 
for using amphetamines to treat or improve cognitive impairment in MS patients.  
METHODS 
 A comprehensive and exhaustive literature search was completed in three databases: 
MEDLINE, Web of Science, and CINAHL. On each database, “amphetamines” and “multiple 
sclerosis” were the only key search terms used. Search filters included only human studies that 
were published or translated in the English language. The method of measuring cognitive 
function was objective using a validated scoring system in each study. Studies were excluded if 
they were conducted greater than 10 years ago, if there were fewer than 30 patients that 
completed the trial, and if they were not current randomized control trials. Each study in this 
systematic review was critically appraised and graded for quality and validity. The grade and 
limitations are summarized in Table 1.  
RESULTS 
 The MEDLINE search displayed 16 studies on Ovid and 15 studies on Pubmed. Web of 
Science found 29 studies and CINAHL revealed 1 study. Of the 61 total studies found, duplicates 
were excluded and three met the inclusion and exclusion criteria set prior to the search. The three 
studies were conducted on patients with cognitive impairment due to multiple sclerosis, 
evaluating the use of amphetamines in comparison to placebo, and measuring cognitive function. 
Each study analyzed a different type of amphetamine for intervention. All studies were 
randomized control trials. The inclusion and exclusion criteria limited the population to patients 
with cognitive impairment due to MS and took measures to minimize the risk of confounding 
factors.  
They each used a validated objective measure for cognitive function, but they were 
slightly different for each study. The Symbol Digit Modalities Test (SDMT) measures visual 
processing speed by quick oral association of symbols with a previously matched digit. The 
Paced Auditory Serial Addition Test (PASAT) measures auditory processing speed by tasking 
participants with quickly adding two verbally given digits. The California Verbal Learning Test, 
second edition, Total Learning (CVLT2-TL) and Delayed Recall (CVLT2-DR) measures 
auditory and verbal learning with an interference and a delay after words are read to the 
participants. The Brief Visual Memory Test-Revised, Total Learning (BVMTR-TL) and Delayed 
Recall (BVMTR-DR) measures visual and spatial memory by showing participants geometric 
shapes and having them draw the shapes after an interference and a delay. At least two of these 
measurements as well as a few others including subjective self-rating tests are taken at baseline 
and at the end of the trial in each study. A summary of these tests and the findings of each study 
are summarized in table II.  
Morrow et al (2009) 
 In this study,6 L-amphetamine was analyzed for improvement in cognitive function in 
clinically defined MS patients. The authors hypothesized that the L-isomer of amphetamine, 
while less potent in increasing dopamine, increases the amount of norepinephrine in the 
hippocampus and cortex. This mechanism could theoretically increase processing speed and 
memory with fewer side effects than the D-isomer, which is commonly used as psychostimulant 
in appetite suppression and attention deficit disorder.6  
 They tested this hypothesis with a group of 151 clinically defined MS patients that were 
cognitively impaired based on conventional norms of in the SDMT, CVLT2-TR, or PASAT. The 
intervention and placebo groups were randomized by a computer program in a 2:1 allocation and 
complete concealment from all participants and clinic staff with the exception of the pharmacist 
supplying the medication. The final sample included 136 patients, 99 received treatment and 37 
placebo. No significant differences in demographics or prognosis between the intervention group 
and control group were found. Participants in the intervention group were started on 5mg and 
titrated up to 30 mg over 14 days. They continued on a maximum of 30 mg until day 29.6  
The primary outcomes are the Subject Global Assessment (SGAC), a subjective self-
rating of cognitive function, and the SDMT, an objective visual processing speed and working 
memory score. Secondary outcomes were the CVLT2-TL, CVLT2-DR, BVMTR-TL, BVMTR-
DR, and the PASAT. The scores of these tests were measured at baseline and day 29, then 
statistically analyzed. Adverse events were reported in 71.3% in the intervention group and 
58.1% in the placebo group. Five participants withdrew due to the events.6 
Delayed recall in both auditory/verbal learning (CVLT-II) and visual/special learning 
(BVMT-R) improved by 48.5% in memory impaired patients with MS on L-amphetamine 
compared to 1.0% on placebo. In the original study, there were no significant findings for the 
primary outcomes, but there were significant results for secondary outcomes. These outcomes 
were reanalyzed by Sumowski et al.6,7 
Morrow et al (2013) 
 The aim of this study8 was to determine if lisdexamfetamine dimesylate (LDX), a 
prodrug that converts to a D-amphetamine, will enhance the cognitive function of MS patients 
with a documented deficit in processing speed or working memory over the duration of 2 
months. They were also assessing for tolerance to the medication and self-reported improvement 
in quality of life.8   
They study included adult males and females with definite MS per 2005 McDonald 
criteria with an Expanded Disability Status Scale core of ≤ 6.5 and a minimum of 1.5 standard 
deviations below the mean on either of the primary outcome measures based of previously 
reported normative data. Of the 63 enrolled and randomized, 48 completed the 8-week study 
with 29 in the LDX group and 19 in the placebo group. Participants started on 30 mg and titrated 
to 70 mg daily. The outcomes were measured at baseline, day 29, and day 57. There were no 
significant differences found in demographics and prognosis between groups.8  
The primary outcomes were the SDMT and PASAT. The secondary outcomes are the 
CVLT2-TL, BVMTR-TL, and Behavioral Rating Inventory of Executive Function for adults 
(BRIEF-A) as a self-perception rating of capacity for activities of daily living. Other secondary 
outcomes assess fatigue with the Fatigue Severity Scale (FSS) and depression or mood with the 
Beck Depression Inventory Fast Screen (BDIFS). There were significant differences found in the 
baseline scores between the two groups. The LDX group had a greater cognitive impairment in 
SDMT, BVMTR-TL, and BRIEF-A scores. The adverse events were reported to be 79.3% in the 
intervention group, but also high in the placebo group at 68.4%. The side effects most frequently 
reported in the intervention group were dry mouth, headache, palpitations, nausea, decreased 
appetite, and anxiety. At least one patient in the LDX group withdrew from the study due to an 
intolerable adverse event. Although none of these events were serious, there was found to be an 
increased heart rate and blood pressure in the LDX group.8 
All quantitative outcomes produced a positive trend; however, only SDMT and CVLT2-
TL showed statistically significant improvement in cognitive function defined by a p-value of 
less than or equal to 0.05. In the SDMT, the mean score increased by 4.6 points in the LDX 
group compared with 1.3 in the placebo group. In CVLT2-TL, participants in the LDX group 
increased their scores by an average of 4.7 points compared to 0.9 points on the placebo. A 
nonsignificant trend is shown in the PASAT and BVMTR-TL scores. This study also made note 
of all adverse events between the two groups, which was a high proportion. 
Morrow & Rosehart 
 This study9 set out to determine if mixed amphetamine salts in extended release form 
could have a positive effect on cognitive function in MS patients. The extended release 
formulation may have less risk for abuse and side effects than other forms of amphetamines. The 
theory behind this thought is that there is a more controlled and steady rate of release of 
dopamine levels in the brain.9 
They conducted a randomized controlled study looking at the cognitive function before 
and after a single dose of mixed amphetamine salts, extended release (MAS-XR). Patients were 
split 1:1:1 into three groups: MAS-XR 5mg, MAS-XR 10mg, and placebo. There were 62 
patients selected to participate based on inclusion and exclusion criteria that were randomized by 
computer program. This included only patients that suffered from cognitive deficits that were 
caused by MS minimizing the possibility for confounders. A total of 10 patients withdrew from 
the study and 52 completed the study. The primary and secondary outcomes were measured in 
the first visit with each participant and then again at the second visit 7 hours (+/- 30 minutes) 
after ingesting the concealed medication. The second visit took place within 28 days of the first 
visit and the participant must have been stable throughout the duration of the study.9 
The primary outcomes measured were SDMT and PASAT. Secondary outcomes were 
BDIFS and FSS. There were no significant differences in demographics, prognosis, or baseline 
scores between the three groups. Only four participants reported nausea, palpitations, and tremor 
on the amphetamine, while two participants on the placebo reported arm tingling and headaches. 
There was no mention of participants withdrawing due to any adverse events.9 
Visual processing speed by SDMT was significantly improved by 5.2 points verses 0.6 
points when comparing the 10mg MAS-XR group to the placebo group.  PASAT demonstrated a 
positive trend, but was not significant. There was no significant change in secondary outcome 
scores. Adverse events were reported and noted throughout the study.9 
DISCUSSION 
 Cognitive impairment continues to impact the lives of MS patients, yet there is still no 
recommended medication to improve this debilitating symptom. Both isomers6,8 as well as mixed 
amphetamine salts9 have showed significant promise through the evidence; however, significant 
limitations were found including some nonsignificant findings, high report of minor adverse 
events, and significant baseline differences. Despite these limitations, the benefits of using 
amphetamines to improve quality of the life in MS patients still seem to outweigh the risks.   
After careful analysis across all relevant studies, the evidence validates that 
amphetamines can play a significant role in improving cognitive impairment in MS patients. 
SDMT scores were consistently measured across all studies in this review. The significant 
increase in objective scores in SDMT in two out of three studies suggests that visual processing 
speed improves with the use of amphetamines.8,9 More improvement was shown in the CVLT2 
scores suggesting amphetamines can have an impact on auditory and verbal learning as well.6  
 The benefits of this review were shown by the improvement of cognitive function, but 
risks must also be outlined. Each study documented adverse events and reported them for 
discussion of safety and tolerance. The Morrow & Rosehart study9 assessing MAS-XR had the 
fewest reported adverse events, which is likely due to the lower amounts of each isomer. There 
were no withdrawals due to side effects. In the Morrow et al (2013) study8 assessing LDX, the 
adverse events were reported to be high in both the LDX group and the placebo group. None of 
the side effects reported were serious, but a number of participants withdrew because of them. 
Similarly in the Morrow et al (2009) study6 assessing L-amphetamine, the adverse events were 
reported to be high in both groups and a few patients also withdrew from the study. The 
intervention groups in both of these studies6,8 did have higher rates of events than the placebo 
group, despite both groups being high. These findings reveal that in the studied doses, the 
amphetamines are safe for these patients; however, the MAS-XR is the leading choice for type of 
amphetamine most efficacious and tolerated by MS patients with the least amount of side effects, 
which is a consistent finding in adult patients with ADHD.10   
 While these were well controlled and randomized studies graded at a low level, there 
were limitations that may give hesitation towards applying the hypothesis to a clinical setting. 
All studies6,8,9 fell short with the given duration the patients were taking the intervention, 
between 1 dose and 14 days on the maximum dose. This limits the ability to assess the long-term 
implication of the amphetamines in terms of both efficacy and tolerance. There was also no 
mention or ability to assess the patients building a tolerance to the amphetamines and needing a 
higher dose to achieve the desired effects. In the study giving a single dose9, there were fewer 
reported adverse events, but this may also be limited by the amount of medication taken and the 
brief period of time it was impacting the patient. Therefore, the study may not have given an 
accurate representation of adverse events and is at risk of reporting bias. The Morrow et al 
(2013) study,8 revealed a serious limitation due to the significant difference between baseline 
SDMT scores and BVMTR scores with greater impairment in the LDX group. This could have 
exaggerated the results of the study in favor of the hypothesis and show inflated cognitive 
improvement in the intervention group.  
All studies6,8,9 had a similar concern because not a single study gave statistically 
significant results in all primary outcomes. This is a serious limitation even though each study 
reveals a significant finding that supported the hypothesis that amphetamines can improve 
cognitive function in MS patients. Furthermore, there were no significant findings that showed a 
subjective improvement from the standpoint of the patient. While the objective results show 
improvement, the question still remains if the amphetamines improve quality of life of the 
patients in their activities of daily living. Lastly, all three studies reviewed had the same lead 
author, which may be seen as a limitation with potential for bias; however, this is not counted as 
a weakness in the evidence due to the author being at the forefront of the research in this field 
and one of the only researchers currently working on the subject. 
  Even with convincing evidence, further research is necessary to completely validate the 
use of amphetamines for cognitive improvement in MS. To apply this research to a clinical 
setting, there must be more information on how this will impact MS patients with comorbidities 
and how the medication is tolerated long term. The next step in research is to first achieve 
consistent and statistically significant results that show that the amphetamines are tolerated and 
efficacious over a long duration. Then, to apply the research to a broader range of patients, study 
how the medication is tolerated and effects MS patients with common comorbidities, such as 
depression. Quite possibly the most important research to be done is how amphetamines can 
impact the quality of life in these patients. Therefore, finding a better method for patients to 
express their self-rating on whether or not the medication improves function and daily life is 
crucial to applying the research in a clinical setting. 
CONCLUSION 
 The results of this systematic review demonstrate that amphetamines may improve 
cognitive function in patients with MS. While there are limitations to the current efforts, there is 
enough evidence to support that this is a topic worthy of further research. For patients with 
reliable follow up for monitoring, the evidence is strong enough to support consideration of the 
use of MAS-XR in MS patients with complaints of cognitive deficits. There are options for MS 
patients to treat depression, pain, and fatigue, but no treatment recommendations exist for 
cognitive function except amphetamines. This is a good option and, so far, the only option for 
patients to regain some mental capacity and function. If research continues, amphetamines may 
become the mainstay of treatment of cognitive function in MS and further research will find 
ways to make its use safer with less adverse effects for patients.   
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Table I. Quality Assessment of Reviewed Articles 
Study 
Desig
n 
Downgrade Criteria Upgrad
e 
Criteria 
Quality Limitation
s 
Indirectnes
s 
Inconsistenc
y 
Imprecisio
n 
Publicatio
n bias 
Morrow 
et al, 
2009 
RCT Not 
Serious 
Not 
Serious 
Not Serious Seriousa Unlikely None Moderat
e 
Morrow 
et al, 
2012 
RCT Seriousb Not 
Serious 
Not Serious Seriousa Unlikely None Low 
Morrow 
& 
Rosehar
t 
RCT Very 
Seriousc 
Not 
Serious 
Not Serious Seriousa Unlikely None Very 
Low 
a Primary outcomes were not all statistically significant for any of the studies included.  
b There is a significant difference in the baseline objective measurements for the primary outcomes between the 
intervention and control group. 
c This is a single-dose study did not address the potential for long term affects and adverse events. Potential 
Reporting bias due to minimal disclosure and analysis of adverse events. 
 
Table II. Summary of Findings 
 Morrow et al (2009)7 Morrow et al (2013)8 Morrow & Rosehart6 
 Significant 
Improvement 
Trend Significant 
Improvement 
Trend Significant 
Improvement 
Trend 
SDMT 
 
N ≤Placebo Y  Y  
PASAT N Positive N Positive N Positive 
CVLT-II – TL  N ≤Placebo Y  -- -- 
CVLT-II – DR Y  -- -- -- -- 
BVMT-R – TL  Y  N Positive -- -- 
BVMT-R – 
DR  
Y  -- -- -- -- 
Y, yes 
N, no 
--, not an outcome of the study 
 
 
 
 
 
 
